But the settlement would eliminate some of the risk from an eventual Supreme Court ruling. Patients would be assured of receiving settlement money even if the Supreme Court rules in Bayer's favor. And Bayer would be protected from potentially larger costs if the high court rules against it. Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, disputes the assertion that Roundup's key ingredient, glyphosate, can cause non-Hodgkin lymphoma. But the company has warned that mounting legal costs are threatening its ability to continue selling the product in U.S. agricultural markets. "Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure," Bayer CEO Bill Anderson said Tuesday. The proposed settlement could total up to $7.25 billion over 21 years and resolve most of the remaining U.S. lawsuits surrounding the cancer-related harms of Roundup. The report notes that more than 125,000 claims have been filed since 2015, and while many have already been settled, this deal aims to cover most outstanding and future claims tied to past exposure.
Individual payouts would vary widely based on exposure type, age at diagnosis, and cancer severity. Bayer can also cancel the deal if too many plaintiffs opt out.
Read more of this story at Slashdot.



